MDNA stock gains ahead of September healthcare conferences

Medicenna Therapeutics Corp. (ISIN CA5846991016) stock advanced strongly on the Toronto Stock Exchange, with the MDNA.TO listing closing at 2.85 Canadian dollars on September 4, 2026, up 22.84 percent from the previous session according to market data for MDNA.TO.

Conference calendar lifts MDNA stock

As reported on September 4, 2026, Medicenna Therapeutics is scheduled to participate in the Wells Fargo 21st Annual Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference in New York during September 2026, putting MDNA stock into focus for biotech investors according to an overview from ad-hoc-news.de.

The same overview highlights that Medicenna Therapeutics Corp., listed under ticker MDNA on the Toronto Stock Exchange and MDNAF on the US-OTCQX, is positioned in the biotechnology sector with a focus on oncology immunotherapies, making investor meetings at large healthcare conferences a key opportunity to discuss trial progress and partnering plans.

Recent price move and peer context

The MDNA.TO closing price of 2.85 Canadian dollars on September 4, 2026 represents a notable single-day gain of 0.53 Canadian dollars compared with the prior closing level of 2.32 Canadian dollars, a move of 22.84 percent according to the Toronto real-time price snapshot for MDNA.TO.

On the US-OTCQX market, the MDNAF listing recently traded at 0.3425 US dollars on September 4, 2026, reflecting a decline of 2.14 percent on that day according to market data that includes MDNAF among Canadian biotech peers.

The divergence between the strong move in MDNA.TO and the weaker MDNAF performance underlines how liquidity and local investor interest on the Toronto Stock Exchange can differ from the US over-the-counter quotation, a factor retail investors should consider when choosing their trading venue.

Pipeline focus in oncology immunotherapies

Medicenna Therapeutics focuses on developing oncology immunotherapies, with its pipeline centered on engineered cytokines and related biologics designed to enhance anti-tumor immune responses; this positioning in cancer immunotherapy makes upcoming scientific and investor presentations at US healthcare conferences particularly important for communicating trial data and partnering strategies.

MDNA stock on Toronto and US-OTCQX

For investors watching MDNA stock, the Toronto Stock Exchange listing under ticker MDNA remains the primary venue, while the MDNAF quotation on the US-OTCQX offers an additional access point in US dollars; as of September 4, 2026, the MDNA.TO closing price of 2.85 Canadian dollars provides the latest benchmark for the company's market valuation.